PAI-1基因多态性与缺血性脑卒中rt-PA静脉溶栓后出血性转化和血管再闭塞的相关性

承德医学院学报 ›› 2022, Vol. 39 ›› Issue (2): 106-110.

PAI-1基因多态性与缺血性脑卒中rt-PA静脉溶栓后出血性转化和血管再闭塞的相关性

周媛, 叶斌^*, 孙静, 宫鑫

蚌埠市第三人民医院,安徽蚌埠 233000

收稿日期:2021-01-11 出版日期:2022-04-10 发布日期:2022-07-29
通讯作者: *
基金资助:
2019年度蚌埠医学院自然科学重点项目（BYKY2019268ZD）

Relationship between PAI-1 Gene Polymorphism and Hemorrhagic Transformation and Vascular Reocclusion after Intravenous Thrombolysis with rt-PA in Ischemic Stroke

ZHOU Yuan, YE Bin^*, SUN Jing, GONG Xin

The Third People's Hospital of Bengbu City, Bengbu, Anhui, 233000, China

Received:2021-01-11 Online:2022-04-10 Published:2022-07-29

摘要/Abstract

摘要： 目的探讨纤溶酶原激活物抑制因子1（PAI-1）基因多态性与缺血性脑卒中rt-PA静脉溶栓后出血性转化和血管再闭塞的相关性。方法将蚌埠市第三人民医院收治的232例接受rt-PA静脉溶栓治疗的急性缺血性脑卒中患者作为研究对象,根据患者是否出现血管再闭塞或出血性转化（HT）,分为再闭塞率组（41例）,HT组（36例）和对照组（155例）。比较2组患者血清PAI-1水平和PAI-1基因675位点多态性,并对不同基因型患者血清PAI-1水平进行分析。结果再闭塞组患者血清PAI-I水平明显高于对照组,而HT组患者血清PAI-I水平明显低于对照组,差异具有统计学意义（P<0.05）。基因型分析结果表明,再闭塞组4G/4G型患者比例明显高于对照组,而HT组患者4G/4G型患者比例明显低于对照组,差异具有统计学意义（P<0.05）。结论急性缺血性脑卒中患者接受rt-PA治疗溶栓治疗后发生血管再闭塞或HT与血清PAI-1水平密切相关,而PAI-1基因675位点4G/4G是影响PAI-1水平重要因素,可能是导致患者对rt-PA溶栓治疗后出现治疗效果差异的主要原因。

关键词: 纤溶酶原激活物抑制物-1, 缺血性脑卒中, 阿替普酶, 血管再闭塞, 出血转化

Abstract: Objective To investigate the relationship between PAI-1 gene polymorphism and cerebral venous thrombolysis occlusion. Methods A total of 232 patients with acute ischemic stroke who received RT PA intravenous thrombolysis in our hospital were selected as the research objects. According to whether the patients had reocclusion or hemorrhagic transformation (HT), they were divided into reocclusion rate group (41 cases), HT group (36 cases) and control group (155 cases). The serum PAI-1 level and PAI-1 gene 675 polymorphism were compared between the two groups, and the serum PAI-1 levels of patients with different genotypes were analyzed. Results The serum PAI-I level in the reoxygenation group was significantly higher than that in the control group, while the serum PAI-I level in HT group was significantly lower than that in the control group (P<0.05). Genotype analysis showed that the proportion of patients with 4G/4G genotype in the reocclusion group was significantly higher than that in the control group, while the proportion of patients with 4G/4G in HT group was significantly lower than that in the control group, the difference was statistically significant (P<0.05). Conclusion The level of PAI-1 in patients with acute ischemic stroke after thrombolytic therapy with RT PA is closely related to the level of serum PAI-1, and 4G / 4G at 675 site of PAI-1 gene is an important factor affecting the level of PAI-1, which may be the main reason for the difference of therapeutic effect after thrombolytic therapy with rt-PA.

Key words: PAI-1, ischemic stroke, rt-PA, vascular reocclusion, hemorrhagic transformation

中图分类号:

R743.3

周媛, 叶斌, 孙静, 宫鑫. PAI-1基因多态性与缺血性脑卒中rt-PA静脉溶栓后出血性转化和血管再闭塞的相关性[J]. 承德医学院学报, 2022, 39(2): 106-110.

ZHOU Yuan, YE Bin, SUN Jing, GONG Xin. Relationship between PAI-1 Gene Polymorphism and Hemorrhagic Transformation and Vascular Reocclusion after Intravenous Thrombolysis with rt-PA in Ischemic Stroke[J]. Journal of Chengde Medical University, 2022, 39(2): 106-110.

参考文献

[1] 郝子龙,刘鸣,李伟,等. 成都卒中登记方法及3123例患者基本特征和功能结局[J]. 中华神经科杂志,2011,44(12):826-831.
[2] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682.
[3] 向晖,吴文清,廖华. 中国人群予以不同剂量阿替普酶治疗急性缺血性脑卒中的Meta-分析[J]. 药物评价研究,2018,41(12):2349-2355.
[4] 苏建,张津华,蒋超. 阿替普酶静脉溶栓治疗急性脑梗死血管再闭塞的影响因素[J]. 中国老年学杂志,2019,39(4):775-777.
[5] 杨绍婉,梁志刚,于国平. 缺血性卒中静脉溶栓后有症状颅内出血:预测和治疗[J]. 国际脑血管病杂志,2018,26(3):201-206.
[6] 卢波,韩莉,吕志昆,等. 急性脑梗死患者血清炎性因子、t-PA、PAI-1变化规律及其意义[J]. 疑难病杂志,2015,(9):906-909.
[7] 战梅,周毓玲,韩忠朝. PAI-1启动子区4G/5G基因多态性对血浆PAI-1水平影响[J]. 中华血液学杂志,2003,24(3):159-160.
[8] 王袆明. 缺血性脑卒中患者凝血功能变化与病情、预后的关系[J]. 血栓与止血学,2017,23(2):293-294,297.
[9] 贾斯达,袁晋青. 血栓形成机制和临床抗栓策略的研究进展[J].中国分子心脏病学杂志,2016,16(3):1748-1752.
[10] Dušanović Pjević M, Beslac Bumbaširevic L, Vojvodic L, et al.Analysis of the Association Between Polymorphisms within PAI-1 and ACE genes and Ischemic Stroke Outcome After rt-PA Therapy[J]. J Pharm Pharm Sci, 2019, 22(1): 142-149.
[11] 谭晓勇,罗茂,卢培林,等. miR-30c 调控 PAI-1对血管内皮细胞活力和迁移的影响[J].中国病理生理杂志,2016,32(12):2199-2204.
[12] 景燕,陆明佳. 再发脑梗死危险因素的研究[J]. 医药前沿,2016,6(25):154-155.
[13] 孙威,杨颖,李雪媛,等. 血浆中PAI-1和TAFI水平与溶栓后出血性转化相关性研究[J]. 中风与神经疾病杂志,2012,29(8):722-725.
[14] Akhter MS, Biswas A, Abdullah SM, et al.The Role of PAI-1 4G/5G Promoter Polymorphism and Its Levels in the Development of Ischemic Stroke in Young Indian Population[J]. Clin Appl Thromb Hemost, 2017, 23(8): 1071-1076.
[15] Hu X, Zan X, Xie Z, et al.Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility[J]. Mol Neurobiol, 2017, 54(1): 328-341.
[16] 梁亮,何红华,蔡静怡,等. 纤溶酶原激活剂抑制物-1基因启动子区4G/5G、-844G/A单核甘酸多态性及其单倍型与缺血性脑卒中的关联分析[J]. 中国实用医药,2014,9(23):99-101.
[17] 王宝香,梅红,彭罕鸣,等. 纤溶酶原激活物抑制因子1基因多态性与过敏性紫癜胃肠道出血的相关性[J]. 临床儿科杂志,2016,34(3):197-200.